OKYO Pharma LTD @OkyoPharma
OKYO focuses on novel GPCR based therapeutics for eye diseases of unmet need and non-opioid analgesics for chronic pain. Nasdaq: $OKYO okyopharma.com London Joined April 2021-
Tweets86
-
Followers141
-
Following40
-
Likes66
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Conference in Boston. $OKYO #Dryeye okyopharma.com/okyo-pharma-an…
Join @OkyoPharma ($OKYO) for a virtual KOL event on Tues. April 9 at 12pm ET, featuring Jay Pepose, MD, PhD who will review the Phase 2 trial evaluating OK-101 in #DED, and Anat Galor, MD, MSPH who will discuss differentiating features of OK-101. Register: brnw.ch/21wIj6u
Thank you for covering our great news today. $OKYO
Thank you for covering our great news today. $OKYO
New price target revision from H.C. Wainwright received today after the positive data released this morning. Raised Target to $7 $OKYO okyopharma.com/investors/inve…
$OKYO OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms tinyurl.com/2yh3ze9a @OkyoPharma #OKYO
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief. $OKYO #clinicaltrials #clinicalresearch @OptometryTimes @OphthTimes @OTEurope @eyewireplus globenewswire.com/en/news-releas…
OKYO will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024. $OKYO Sign…
Today OKYO announced that we will be releasing comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on March 22, 2024. The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth. $OKYO okyopharma.com/okyo-pharma-to…
Following on from our great news last week of the FDA approval of our IND for NCP, H.C Wainwright have raised their price target of OKYO up to $6 and Reit a Buy rating. Full Report an be found on our website via this link: okyopharma.com/investors/inve… $OKYO
OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so. Learn more: optometrytimes.com/view/fda-accep…
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain (NCP). NCP is a major unmet medical need and listed as an Orphan disease. $OKYO #neuropathiccornealpain #NCP #orphandrugs #orphan okyopharma.com/okyo-pharma-re…
OKYO Pharma Today Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board. $OKYO #SAB #dryeyedisease #NCP okyopharma.com/okyo-pharma-an…
BIG NEWS TODAY. OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease. $OKYO #JPM2024 okyopharma.com/okyo-pharma-an…
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 $OKYO okyopharma.com/okyo-pharma-to…
Today we Announced Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit. Another step closer to top-line data this month. $OKYO #DED okyopharma.com/okyo-pharma-an…
$OKYO OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain tinyurl.com/yt9wrl32 @OkyoPharma #OKYO
Today we Announced Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”). Another potential indication for OK-101 which is currently in a phase 2 trial for Dry Eye Disease. $OKYO #IND #NCP #DED okyopharma.com/okyo-pharma-an…
$OKYO OKYO Pharma phase II dry eye trial making encouraging progress tinyurl.com/yoba5dsx @OkyoPharma #OKYO
Today we Announced Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED"). Topline data scheduled for release in December 2023. $OKYO #DryEye #DED okyopharma.com/okyo-pharma-an…
Today we announced that we have completed full enrollment in our phase 2 trial in Dry Eye Disease. We look forward to top line data expected by the end of this year. $OKYO #Phase2 okyopharma.com/okyo-pharma-co…
bellaguo @RealIsabella7
1 Followers 95 Following Sales Manager-Tosun Pharmaceutical Exporting & Importing APIs, RLDs, Formulations, Impurity standards, Reference standards, Pharmaceutical intermediate, etc.
Watson Genomics @WatsonGenomics
61 Followers 1K Following
Sameer @Sameer71416033
1 Followers 11 Following
송종혁 @ppohbro
0 Followers 2 Following
Matthew Herald @YourEverydaySci
452 Followers 2K Following Be a good person, do cool things. UTK '19 l UoB ‘22 | He, His, Him
Bearded Trader @Luvtheoutdoors8
865 Followers 1K Following My tweets are my own opinions, I am not a financial advisor. CEO of Survival Equals Life. Check us out:https://t.co/ZPjeGeHKlj
aztecmonkey007 @aztecmonkey007
127 Followers 618 Following
Janelle Perry @PerrJanell
66 Followers 5K Following
Madiha Ghani @mjghan
351 Followers 2K Following Postdoctoral fellow @UCL. Working on developmental biology of C.elegans | Ph.D. @tsinghua_uni | Cell Biologist I Tweets & opinions are my own.
Lin Milberger @milberge_l
75 Followers 5K Following
Steve.higgins14 @Higgins14Steve
362 Followers 153 Following
Mia Andrew @MiaAndrew189336
35 Followers 5K Following
Boudin @boudin420
2K Followers 2K Following I've traded everything from .0001 to futures. Swinging Bios into catalysts for now. Always learning. Lets get dat graaavy! GeauxTigers!! #CajunBull
DSI, a PLG Company @DSInPharmatics
311 Followers 1K Following DSI is a full service CMC Drug Development Consulting Firm, assisting emerging Biotech and Pharma sponsors with CMC, Regulatory and QA for NCEs & Biologics
Yahaya Mohammed @ym_balarabe
104 Followers 974 Following
Mark Yu @markvbyu
20 Followers 139 Following
chosery @chosery298331
83 Followers 194 Following
Emre @CelikayEmre
38 Followers 294 Following
moe @ceTbPmWjYBvtyBf
21 Followers 98 Following
jimmy stevens @trumbulljimmy
25 Followers 10 Following
QRD Pharma LLC @QRDPharmaLLC
4 Followers 54 Following QRD Pharma is a science-oriented CRO, offering a wide range of services focused on the bioanalysis of small molecules, peptides, and biomarkers.
CY Partners @CYPartners
663 Followers 3K Following If you're hiring or job-seeking, we specialise in recruiting for all levels of talent in Science, Pharma, Clinical, Chemicals and Biotech.
Lisa Pattullo @LisaPattullo
110 Followers 421 Following Mum to 👩👦👧, 6 🐴 , 1 🐶 and four 🐥 and wife to 👱♂️
TLC Group Comparator .. @RLDSourcing
37 Followers 254 Following Group Comparator Drug Sourcing for new drug development and clinical trials, Global Drug Sourcing, Finished drug product manufacturing, CDMO, Dossier, eCTD,
Richard Perry @rp6577
6 Followers 19 Following
JA @JA9791
135 Followers 842 Following
Celling Alpha @CellingAlpha
184 Followers 3K Following Tweets about biomedical sciences and finance. Ph.D., Not financial advice. Do your own research.
Dark Horse @darkhorsealpha
7 Followers 63 Following
EYOB ASSEFA @jobacute5300
178 Followers 477 Following
Exhibitors Voice @ExhibitorsV
286 Followers 466 Following Digital Marketing Solution Provider for B2B Event Industry
👑 WallStreetSignal.. @BillyGains01
2K Followers 3K Following My TWEETS are not Financial advice; they are strictly my opinions. #STOCKS #PENNYSTOCKS #TRADER #INVESTOR #STOCK #MARIJUANASTOCKS #NASDAQ #OTC #WALLSTREET
JPepp @jpepp50
25 Followers 362 Following
Avenueplus Group @avenueplusng
41 Followers 6 Following Parent Comapny @foodrundotng @ikondigital.co
gxzhen130155 @gxzhen130184003
62 Followers 23 Following
Eyewire+ @eyewireplus
9K Followers 912 Following Eyewire+ keeps readers updated with the latest in the #ophthalmology field, featuring breaking news from press releases, medical journals, vision publications,
Bio Stocks™ @BioStocks
65K Followers 84 Following Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.
Alcon @SeeAlconScience
743 Followers 1K Following Learn about the science behind innovations from Alcon. This channel is intended for US Based HCPs only. See our community guidelines: https://t.co/LSsWZB1Wlv
Vision Monday @VisionMonday
20K Followers 2K Following The optical industry's leading news website, covering all things eyecare and vision care related, including eyewear, lenses, technology and management.
Pedram Hamrah @PedramHamrah
2 Followers 144 Following
Tufts Medical Center @TuftsMedicalCtr
23K Followers 893 Following Tufts Medical Center is an academic teaching hospital in Boston.
Bausch + Lomb @BauschLomb
18K Followers 158 Following This is the official U.S. Bausch + Lomb Twitter page. We're dedicated to helping people see better to live better.
Novartis @Novartis
300K Followers 529 Following An innovative medicines company working to reimagine medicine. See our community guidelines: https://t.co/PnsiaxwOuy
Webull @WebullGlobal
127K Followers 110 Following 0 commission trading and all the data you can handle so that you can execute on informed decisions. Disclosure: https://t.co/UUs9JTrzXk
GoldmanSmallCap @GoldmanSmallCap
2K Followers 1K Following We publish sponsored and non-sponsored market and small cap research. Perform due diligence and refer to our disclosures before investing. https://t.co/ofi6iElKeq
Andrew Scott @AndrewScottTV
6K Followers 2K Following Director, Co-Founder - JustStocks (https://t.co/agSZ2aXpGm) Non Executive Director - ECR Minerals PLC (LON:ECR)
ASCRS @ASCRStweets
13K Followers 1K Following American Society of Cataract and Refractive Surgery: an international non-profit advancing the art and science of ophthalmic surgery.
Seeking Alpha Market .. @MarketCurrents
89K Followers 1 Following Real-time stock market news from Seeking Alpha.
Zacks SCR @ZacksSmallCap
5K Followers 181 Following Zacks Small Cap Research provides equity research on #smallcap and #microcap firms. https://t.co/W18in20Snh
Share_Talk ™ @Share_Talk
23K Followers 98 Following @Share_Talk official Twitter account https://t.co/dr4HNUXWRh The digital stock market - news platform with the #UK highest engagement figures across #socialmedia
Investor News @newsfilterio
23K Followers 177 Following Run by investors, for investors. Real-time: PRs Gov. contract awards Earnings M&As FDA approvals Insider trades SEC filings And more Not investment advice
Market Wire News @marketwirenews
63K Followers 0 Following Market Wire News is a news platform to help research, connect and engage
Hanson Wade @HansonWade
354 Followers 11 Following We put on events all over the world, giving people clarity on their jobs and industries. We build careers, help companies and highlight progress
Genentech @genentech
128K Followers 237 Following Official Twitter for Genentech. See our community guidelines here: https://t.co/yas51FPhKU
Genentech Ophthalmolo.. @GenentechEye
12K Followers 136 Following Official Twitter for Genentech Ophthalmology. See our community guidelines here: https://t.co/6TP61w1dJT
Review of Ophthalmolo.. @RevOphth
6K Followers 256 Following News, information & interesting stuff from the editors of Review of Ophthalmology. This account has no commercial sponsorships.
ELS Ophthalmology @ELS_Ophthal
11K Followers 108 Following We publish the world's finest selection of ophthalmology reference books, periodicals, eBooks, apps, and online resources.
Clinical and Experime.. @Clin_Ophthalmol
4K Followers 1K Following Journal of Clinical and Experimental Ophthalmology considers articles within ophthalmology and its research areas. Contact: [email protected]
IOVS Journal @ARVOiovs
5K Followers 577 Following Investigative Ophthalmology & Visual Science (IOVS) is an open access, peer-reviewed online journal of the Association for Research in Vision in Ophthalmology.
Ophthalmology Innovat.. @OISTWEETS
9K Followers 1K Following Largest & Original Producer of World-Class Ophthalmology Innovation Conferences & Content Since 2009.
American Journal of O.. @AJOphthalmology
8K Followers 100 Following Twitter feed for the American Journal of Ophthalmology. Published monthly since 1884. An Elsevier journal.
Ophthalmology Times E.. @OTEurope
26K Followers 289 Following Ophthalmology Times Europe presents cutting-edge advancements in surgery, drug therapy, technology and clinical diagnosis.
Ophthalmology Info @eurospan_ophth
4K Followers 3K Following Ophthalmology! Keep up-to-date with the latest ophthalmic news, information, and new titles with Eurospan. Let us know what you think!
AAO @aao_ophth
42K Followers 274 Following The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons.
OphthalmologyWeb @ophthalmologywb
8K Followers 128 Following Online resource for Ophthalmologists looking for latest news, original editorial, videos, CME, and product information.
Ophthalmology @AAOjournal
22K Followers 96 Following Ophthalmology, Ophthalmology Retina, Ophthalmology Glaucoma, & Ophthalmology Science - a family of peer-reviewed journals from the AAO @aao_ophth
JAMA Ophthalmology @JAMAOphth
19K Followers 168 Following JAMA Ophthalmology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Ora, Inc. @oraclinical
838 Followers 497 Following Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia.
Zaks Traders Cafe @ZaksTradersCafe
26K Followers 4K Following ZTC asks the questions others shy away from, while helping traders and investors gain an edge and uncover hidden gems.
Optical Insider @OpticalInsider
142 Followers 225 Following Delivering the latest Optical news straight to your inbox every Tuesday and Friday 🕶 Official Media Partner of @100Optical
Ophthalmology Times @OphthTimes
27K Followers 793 Following The leading content resource for #Ophthalmology | Follow us on Facebook: https://t.co/7wyuVtHjX1…
Proactive @proactive_UK
30K Followers 3K Following We lead the world in up-to-the-minute, multi-media news provision. We receive compensation for publishing content here on behalf of our clients. T&Cs apply
AmbioPharm, Inc. @Ambio_peptides
208 Followers 512 Following AmbioPharm is a full-service peptide CDMO. We manufacture research & cGMP #peptides at small & large scales, perform pilot manufacturing, & process development.Join @OkyoPharma ($OKYO) for a virtual KOL event on Tues. April 9 at 12pm ET, featuring Jay Pepose, MD, PhD who will review the Phase 2 trial evaluating OK-101 in #DED, and Anat Galor, MD, MSPH who will discuss differentiating features of OK-101. Register: brnw.ch/21wIj6u
Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including significant improvement in #ocularpain relief, #conjunctivalstaining and #TBUT in patients with #DED. @OkyoPharma Click to read more! bit.ly/3TFGXMu
$OKYO -HC Wainwright raises OKYO Pharma price target to $7 from $6, Buy rating
OKYO Pharma, a clinical-stage biopharmaceutical company, announced additional findings from clinical data set analyses from its Phase 2 clinical trial evaluating the safety and efficacy of OK-101, an ophthalmic solution in patients with DED. Read more: ow.ly/x81E50QZzjR
$OKYO OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms tinyurl.com/2yh3ze9a @OkyoPharma #OKYO
🚨The #FDA cleared the first investigational new drug application for neuropathic corneal pain 🚨 Read more 👇 #OcularSurgeryNews #Cornea #Ophthalmology @OkyoPharma bit.ly/3upE5uv
Check in to see what you missed from Optometry Times this week: ow.ly/wi6M50QzMzr
#customers #News #ClinicalStudy #Pain #Corneal Breakthrough in Ocular Therapy: FDA Approves OKYO Pharma's OK-101 for Neuropathic Corneal Pain: $OKYO Neuropathic corneal pain (NCP) is a debilitating ocular condition characterized by persistent pain in… dlvr.it/T2Wklh
$OKYO (+24.5% pre) OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain ooc.bz/l/24527
OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so. Learn more: optometrytimes.com/view/fda-accep…
$OKYO OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial @OkyoPharma #OKYO
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain $OKYO healthstockshub.com/news/nasdaq/ok…
OKYO Pharma has reported positive safety and efficacy results in its Phase 2 of OK-101 ophthalmic solution in subjects with dry eye disease, according to findings from by a first-in-human, randomized, double-masked, placebo-controlled trial. Read more: ow.ly/1Btb50Qpjbl
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board $OKYO healthstockshub.com/news/nasdaq/ok…
@OkyoPharma announced safety and efficacy results in its phase 2 trial evaluating the safety and efficacy of OK-101 ophthalmic solution in patients with dry eye disease (DED). bit.ly/48vLTcV
$OKYO Last Patient Enrolled in OK-101 Phase 2 Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit. Topline Data in December.
$OKYO OKYO Pharma has dry eyes as a lucrative prize in its sights tinyurl.com/y3jm2b3k @OkyoPharma #OKYO
$OKYO OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit tinyurl.com/2xd5t4yc @OkyoPharma #OKYO
$OKYO OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain tinyurl.com/yt9wrl32 @OkyoPharma #OKYO
$OKYO OKYO Pharma phase II dry eye trial making encouraging progress tinyurl.com/yoba5dsx @OkyoPharma #OKYO
Trends for United States
You might like
